Nanox Expands UK Footprint with Vertec Scientific Partnership for AI Bone Health Solution
Event summary
- Nanox AI Ltd. has signed a three-year exclusive sales reseller agreement with Vertec Scientific Ltd. for the commercialization of HealthOST in the UK.
- HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution for analyzing routine CT scans to assess spinal musculoskeletal diseases like osteoporosis.
- The agreement includes minimum annual license commitments and leverages Vertec's 50-year expertise in DXA and bone health solutions in the UK.
- NICE recommended HealthOST in November 2025 for opportunistic detection of vertebral fragility fractures in the NHS.
- Nanox aims to integrate HealthOST with existing PACS systems to enable timely preventive care without additional imaging or patient time.
The big picture
This partnership marks Nanox's strategic push into the UK's bone health market, capitalizing on the growing demand for AI-driven preventive diagnostics. The deal underscores the shift toward integrating AI solutions into existing healthcare workflows, particularly in opportunistic screening for chronic conditions like osteoporosis. With Vertec's deep market expertise, Nanox aims to position HealthOST as a standard tool in UK clinical practice, potentially expanding its reach beyond the UK in the future.
What we're watching
- Market Penetration
- Whether Nanox can leverage Vertec's established UK network to achieve significant adoption of HealthOST in NHS and private healthcare settings.
- Regulatory Alignment
- How NICE's recommendation will influence broader NHS adoption and reimbursement policies for AI-driven diagnostic tools.
- Execution Risk
- The pace at which Nanox can integrate HealthOST with diverse PACS systems and maintain minimum license commitments over the three-year term.
Related topics